BMG Pharma forms long-term partnership with Luqa Pharmaceuticals in China

Published: 12-Jul-2013

Luqa will exclusively register and commercialise BMG\'s dermatology, oral care and cancer support therapy products


BMG Pharma, a specialist pharmaceutical firm based in Milan, Italy has formed a long-term partnership with Luqa Pharmaceuticals for the commercialisation of BMG’s products in China and Hong Kong.

Under the terms of the agreement, Luqa will exclusively register and commercialise BMG's dermatology, oral care and cancer support therapy products.

The tie-up will enable Luqa rapidly to expand its dermatology offering and enter the oral and supportive care markets in China.

The partnership covers IaluXid, a non-antibiotic, combination gel formulation treating skin infections; GelX and GelX Xero for preventing and treating oral mucositis and xerostomia; and Aftacure, a treatment for aphthous ulcers and mouth lesions. Luqa expects to launch this family of products in China from late 2015 onwards.

‘BMG's proven innovation capabilities complements Luqa's deep understanding of the evolving needs in China's healthcare market,’ said Marco Mastrodonato, President and CEO of BMG Pharma. ‘This long-term partnership is a major milestone for BMG as it opens us the door to the most exciting healthcare market in the world.’

Robert Braithwaite, CEO of Luqa Pharmaceuticals, said the partnership with BMG is ‘in line with our strategy to build a portfolio of innovative and high-growth potential products through targeted partnerships’.

He added: ‘BMG Pharma's products complement our portfolio of innovative therapies, and we look forward to develop them into leading healthcare brands.’

You may also like